Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 7/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.30 |
| ▸ | CTSG | P08311 | 1/20 | 0.30 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.30 |
| ▸ | CMA1 | P23946 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27832488 | 1.00 | CTSK (0.40) | CTSKCTSSPRSS1CTSGCTRB1 | |
| SCHEMBL27832487 | 0.84 | CTSK (0.41) | CTSKCTSSPRSS1CTSGCTRB1 | |
| SCHEMBL27812361 | 0.84 | CTSK (0.41) | CTSKCTSSPRSS1CTSGCTRB1 | |
| SCHEMBL29187868 | 0.83 | CTSK (0.54) | CTSKCTSSPRSS1CTSGCTRB1 | |
| SCHEMBL28680208 | 0.82 | PRKCA (0.37) | — | |
| SCHEMBL29271806 | 0.82 | PRKCA (0.37) | — | |
| SCHEMBL27910718 | 0.81 | CTSK (0.38) | CTSKCTSSCA1CA2 | |
| SCHEMBL27726431 | 0.81 | CTSK (0.38) | CTSKCTSSCA1CA2 | |
| SCHEMBL27834093 | 0.81 | CTSK (0.38) | CTSKCTSSCA1CA2 | |
| SCHEMBL29118081 | 0.80 | CTSK (0.48) | CTSKPRSS1CTSGCTRB1CMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102112130-A | Pyrazine derivatives as epithelial sodium channel blockers | NOVARTIS AG | 2011-06-29 | — | — | CN | disclosed |
| CN-102015662-A | 3,5-diamino-6-chloro-pyrazine-2-carboxylic acid derivatives and their use as epithelial sodium channel blockers for the treatment of arway diseases | NOVARTIS AG | 2011-04-13 | — | — | CN | disclosed |